TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8311588

Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia with systemic normothermia (≥ 35 degrees C)
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Intermittent cold oxygenated crystalloid cardioplegia and moderate systemic hypothermia (≤ 28 degrees C)
Number of subjects: 1001
Study: 3257805

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation combined with voluntary muscle contractions
Number of subjects: 23

Group type: COMPARATOR
Intervention: Voluntary muscle contractions only (Control)
Number of subjects: 23
Study: 1396833

Group type: EXPERIMENTAL
Intervention: 80 mg of full length unglycosylated single‐chain‐urokinase plasminogen activator (saruplase)
Number of subjects: 401

Group type: COMPARATOR
Intervention: 1.5 million IU of streptokinase delivered over a 60 min period
Number of subjects: 401
Study: 277069

Group type: EXPERIMENTAL
Intervention: 10 per cent urea peroxide solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal oral hygiene instructions
Number of subjects: 60
Study: 31029863

Group type: EXPERIMENTAL
Intervention: Riboflavin intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (MTHFR 677CC genotype)
Number of subjects: 75
Study: 30688082

Group type: EXPERIMENTAL
Intervention: Early limited‐volume DHM supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exclusive breastfeeding
Number of subjects: 60
Study: 28606098

Group type: EXPERIMENTAL
Intervention: PedsQL Sickle Cell Disease Module
Number of subjects: 0
Study: 25550288

Group type: EXPERIMENTAL
Intervention: Loozit() group programme with additional therapeutic contact (telephone coaching, SMS, emails)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Loozit() group programme without additional therapeutic contact
Number of subjects: 151
Study: 23438496

Group type: EXPERIMENTAL
Intervention: 45-g whey supplement
Number of subjects: 10

Group type: COMPARATOR
Intervention: 45-g maltodextrin control
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Urinary urea
Number of subjects: 10
Study: 20861415

Group type: EXPERIMENTAL
Intervention: Propofol infusion based on lean body weight (LBW)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol infusion based on total body weight (TBW)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group receiving propofol infusion based on total body weight (TBW)
Number of subjects: 60
Study: 19777735

Group type: EXPERIMENTAL
Intervention: Agomelatine (Valdoxan®)
Number of subjects: 0
Study: 16516954

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol dose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14739053

Group type: EXPERIMENTAL
Intervention: Combination therapy (repaglinide plus pioglitazone)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Repaglinide
Number of subjects: 246

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 246
Study: 11691689

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 53
Study: 9140529

Group type: EXPERIMENTAL
Intervention: Bread baked with alpha-amylase and hemicellulase
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bread baked without enzymes (control)
Number of subjects: 17
Study: 7965263

Group type: EXPERIMENTAL
Intervention: Losartan 5 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Losartan 10 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Losartan 75 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Losartan (all doses)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Losartan (150 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 3111914

Group type: EXPERIMENTAL
Intervention: sorbinil (125 mg daily for 6 mo)
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 31598837

Group type: EXPERIMENTAL
Intervention: Nonclinical studies with translational robustness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larger studies/programs to maintain statistical power
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consideration of bias in translational studies
Number of subjects: 0
Study: 31270665

Group type: EXPERIMENTAL
Intervention: Tor Vergata Stroke Score (TVSS)
Number of subjects: 270
Study: 27518491

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fibromyalgia Education (control)
Number of subjects: 16
Study: 26136485

Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (TH) 40 mg IA injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Methylprednisolone acetate (MA) 40 mg IA injection
Number of subjects: 100
Study: 22732768

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 10
Study: 21149651

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Educational materials (Control)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Change in CES-D scores
Number of subjects: 125
Study: 18082489

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear bone marrow cells (mBMC)
Number of subjects: 100
Study: 16940835

Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg single dose) plus iron supplements
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Placebo plus iron supplements
Number of subjects: 1042
Study: 12898818

Group type: EXPERIMENTAL
Intervention: Psychotherapy as a completion of traditional treatment for vocal nodules
Number of subjects: 0
Study: 9952383

Group type: EXPERIMENTAL
Intervention: HBY 097 monotherapy (250 mg three times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine plus HBY 097 (750 mg three times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with high‐dose HBY 097
Number of subjects: 0
Study: 7674680

Group type: EXPERIMENTAL
Intervention: Memory tests with background distractor during intoxication
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Memory tests without background distractor during intoxication
Number of subjects: 40

Group type: COMPARATOR
Intervention: Memory tests with background distractor while sober
Number of subjects: 40

Group type: COMPARATOR
Intervention: Memory tests without background distractor while sober
Number of subjects: 40
Study: 1970427

Group type: EXPERIMENTAL
Intervention: Clozapine (75 to 250 mg/day, mean 170.8)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6993250

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination of oxprenolol and hydralazine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hydralazine (during placebo period)
Number of subjects: 29
Study: 31993819

Group type: EXPERIMENTAL
Intervention: Doxapram (1 mg/kg bolus and 1 mg/kg/h infusion)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Doxapram and Placebo
Number of subjects: 56
Study: 29800299

Group type: EXPERIMENTAL
Intervention: Guidewire catheter (Accucath 18-gauge)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard 18-gauge peripheral intravenous catheter
Number of subjects: 93
Study: 24612629

Group type: EXPERIMENTAL
Intervention: Integrated Psychological Intervention (IPI), including cognitive behaviour therapy for 12 months
Number of subjects: 128

Group type: COMPARATOR
Intervention: Supportive Counselling (SC) for 12 months
Number of subjects: 128
Study: 25381560

Group type: EXPERIMENTAL
Intervention: TNFi therapy etanercept (ETN) combined with methotrexate (MTX)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard therapy with MTX with or without additional synthetic disease modifying anti-rheumatic drugs
Number of subjects: 120
Study: 23006447

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 every 21 days) plus best supportive care (BSC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 every 21 days) plus BSC
Number of subjects: 55
Study: 21090832

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 or 80 mg/day plus amlodipine 5 or 10 mg/day
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Single-pill telmisartan/amlodipine
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Telmisartan/amlodipine
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Telmisartan or amlodipine monotherapy
Number of subjects: 1461
Study: 17642037

Group type: EXPERIMENTAL
Intervention: Counselling on medical rehabilitation (Intervention Group - IG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control Group - CG)
Number of subjects: 0
Study: 16166930

Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg per os 1 hour prior to the procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 0
Study: 12013195

Group type: EXPERIMENTAL
Intervention: Aspirin 10%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aspirin 1%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mepyramine 5%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 24
Study: 10413273

Group type: EXPERIMENTAL
Intervention: Higher-dose platelet component (HDP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lower-dose platelet component (LDP)
Number of subjects: 46
Study: 7496234

Group type: EXPERIMENTAL
Intervention: Diet S (21% energy from saturated fat)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Diet P (10% energy from saturated fat)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Diet S and P
Number of subjects: 67
Study: 2197381

Group type: EXPERIMENTAL
Intervention: Meclofenamate 100 mg plus codeine 60 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Meclofenamate 50 mg plus codeine 30 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Meclofenamate 100 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 6992844

Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide cream applied three times daily
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide cream applied once daily
Number of subjects: 95

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 95
Study: 31605735

Group type: EXPERIMENTAL
Intervention: Early integrated palliative home care (PHC) with an average of 3.4 visits, focusing on disease insight, symptom management, and care planning.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Early integrated palliative home care (PHC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 39
Study: 31154809

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 28244718

Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa L. (HS) tea for 30 days
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Gynostemma pentaphyllum Makino (GP) tea for 30 days
Number of subjects: 48
Study: 27007076

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 62
Study: 24676694

Group type: EXPERIMENTAL
Intervention: 0.035 mg ethinyl estradiol + 2 mg cyproterone acetate (group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 0.03 mg ethinyl estradiol + 3 mg drospirenone (group B)
Number of subjects: 52
Study: 23141085

Group type: EXPERIMENTAL
Intervention: FFR > 0.75 group
Number of subjects: 106

Group type: COMPARATOR
Intervention: FFR ≤ 0.75 group
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: MLD ≥ 1.6 mm
Number of subjects: 106
Study: 19071184

Group type: EXPERIMENTAL
Intervention: ACAM1000
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ACAM2000
Number of subjects: 90

Group type: COMPARATOR
Intervention: Dryvax
Number of subjects: 90
Study: 17938746

Group type: EXPERIMENTAL
Intervention: Dental amalgam treatment
Number of subjects: 507

Group type: COMPARATOR
Intervention: Resin composite treatment
Number of subjects: 507
Study: 15866414

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham ultrasound (US)
Number of subjects: 12
Study: 12123116

Group type: EXPERIMENTAL
Intervention: New glass ionomer filling material (Chem‐Flex)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control material fillings
Number of subjects: 41
Study: 10225582

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (400 mg, every 8 h)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Intravenous standard therapy (beta-lactam)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (400 mg, every 8 h) plus beta-lactam
Number of subjects: 540

Group type: COMPARATOR
Intervention: Intravenous standard therapy (aminoglycoside plus beta-lactam)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg, every 12 h)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Standard oral therapy
Number of subjects: 540
Study: 1639052

Group type: EXPERIMENTAL
Intervention: Vitamin A (200,000 IU of retinyl palmitate)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 6376479

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 30499929

Group type: EXPERIMENTAL
Intervention: In the Classroom Web site (treatment group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: LEARNet Web site (control group)
Number of subjects: 100
Study: 28847146

Group type: EXPERIMENTAL
Intervention: On-X mechanical valve
Number of subjects: 360

Group type: COMPARATOR
Intervention: St Jude mechanical valve
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: On-X mechanical valve (25 mm size)
Number of subjects: 360

Group type: COMPARATOR
Intervention: St Jude mechanical valve (25 mm size)
Number of subjects: 360
Study: 27266282

Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 7453

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 7453
Study: 25751673

Group type: EXPERIMENTAL
Intervention: Isotonic intravenous fluids (sodium chloride, 0.9%, and dextrose, 5%)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hypotonic intravenous fluids (sodium chloride, 0.45%, and dextrose, 5%)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hypotonic intravenous fluids
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Isotonic intravenous fluids
Number of subjects: 110
Study: 24331798

Group type: EXPERIMENTAL
Intervention: Tirofiban (10 µg/kg bolus within 3 min followed by 0.10‐0.15 µg×kg(‐1)×min(‐1) for 36 h i.v.)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control (saline i.v. for 36 h)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control
Number of subjects: 246
Study: 20347467

Group type: EXPERIMENTAL
Intervention: Continuous smoking
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Abstinence with transdermal nicotine patch (TNP)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Abstinence with placebo patch
Number of subjects: 78

Group type: COMPARATOR
Intervention: Never smokers (control)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Smokers (vitamin C levels)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Smokers (PINP levels)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 78
Study: 18554238

Group type: EXPERIMENTAL
Intervention: 0.5 mg entecavir
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 1 mg entecavir
Number of subjects: 84
Study: 21794296

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Overall NSAID therapy
Number of subjects: 233
Study: 14670418

Group type: COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Laser-assisted subepithelial keratectomy (LASEK)
Number of subjects: 108

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 108
Study: 10971602

Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) 25 microg/kg daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF)
Number of subjects: 10
Study: 9256564

Group type: EXPERIMENTAL
Intervention: 10-week school-based child- and parent-focused psychosocial intervention
Number of subjects: 128

Group type: COMPARATOR
Intervention: Monitoring group
Number of subjects: 128
Study: 8285335

Group type: EXPERIMENTAL
Intervention: isoflurane-fentanyl anaesthesia with nitrous oxide in oxygen
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: propofol-fentanyl anaesthesia with air in oxygen
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: propofol-fentanyl anaesthesia with nitrous oxide in oxygen
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 4 l.min‐1 of oxygen by nasal catheter
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Postoperative days 1, 2 and 3
Number of subjects: 42
Study: 3104180

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches delivering 10 mg/24 hours
Number of subjects: 10
Study: 31982957

Group type: EXPERIMENTAL
Intervention: DCM patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DCM patients with mild/moderate clinical status
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DCM patients with severe clinical status
Number of subjects: 28

Group type: COMPARATOR
Intervention: Controls (TAAA)
Number of subjects: 28
Study: 29187046

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 26626365

Group type: EXPERIMENTAL
Intervention: Formula supplemented with bovine milk-derived oligosaccharides and Bifidobacterium animalis subsp. lactis (B. lactis) strain CNCM I-3446
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-supplemented control formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breastfed infants (reference group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test formula (BMOS + B. lactis)
Number of subjects: 0
Study: 24786196

Group type: EXPERIMENTAL
Intervention: Jitai tablet treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Baseline levels in heroin addicts
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 99
Study: 22989359

Group type: EXPERIMENTAL
Intervention: Individualised FSH regime (150 IU/day, 225-450 IU/day, and 100 IU/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard FSH regime
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Individualised FSH regime
Number of subjects: 100
Study: 20466951

Group type: EXPERIMENTAL
Intervention: Dental practitioner advice and brief counseling intervention including nicotine replacement therapy
Number of subjects: 2549

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2549
Study: 18085424

Group type: EXPERIMENTAL
Intervention: Tetracycline HCL (20%) sclerotherapy after aspiration
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (aspiration without sclerotherapy)
Number of subjects: 70
Study: 15819670

Group type: EXPERIMENTAL
Intervention: DELFIA analysis in vCJD patients
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DELFIA analysis in non-CJD neurological patients
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: DELFIA analysis in sCJD patients
Number of subjects: 4

Group type: COMPARATOR
Intervention: Flow cytometry in neurological controls
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Flow cytometry in all groups
Number of subjects: 4
Study: 12554916

Group type: EXPERIMENTAL
Intervention: Vitamin K prophylaxis in severely ill patients on extended periods of antibiotics and inadequate diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged antibiotic therapy
Number of subjects: 0
Study: 10477036

Group type: EXPERIMENTAL
Intervention: Omega-3 and omega-6 EFAs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 20
Study: 8753919

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intradural anesthesia
Number of subjects: 50
Study: 1840166

Group type: EXPERIMENTAL
Intervention: Xylonest 3% Octapressin
Number of subjects: 220

Group type: COMPARATOR
Intervention: Scandicain
Number of subjects: 220
Study: 6366137

Group type: EXPERIMENTAL
Intervention: 3 years of chemotherapy
Number of subjects: 316

Group type: COMPARATOR
Intervention: 5 years of chemotherapy
Number of subjects: 316
Study: 31747948

Group type: EXPERIMENTAL
Intervention: 9 weeks trastuzumab
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: 1 year trastuzumab
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Prognostic stage
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Anatomic stage
Number of subjects: 1244
Study: 29787831

Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (OEA) 125 mg capsules, two capsules daily for 60 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (starches)
Number of subjects: 60
Study: 27236486

Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual testosterone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24905918

Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no static stretching)
Number of subjects: 11